Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12
The authors investigated immunogene therapy for malignant glioma to determine whether its therapeutic efficacy could be improved. Four groups of 203-glioma-bearing mice were treated with injections of phosphate-buffered saline, Semliki Forest virus (SFV)-LacZ, retrovirus vector DFG-interleukin (IL)-...
Gespeichert in:
| Veröffentlicht in: | Neurosurgical focus 2000-12, Vol.9 (6), p.e7-6 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6 |
|---|---|
| container_issue | 6 |
| container_start_page | e7 |
| container_title | Neurosurgical focus |
| container_volume | 9 |
| creator | Yamanaka, R Zullo, S A Tanaka, R Ramsey, J Blaese, M Xanthopoulos, K G |
| description | The authors investigated immunogene therapy for malignant glioma to determine whether its therapeutic efficacy could be improved.
Four groups of 203-glioma-bearing mice were treated with injections of phosphate-buffered saline, Semliki Forest virus (SFV)-LacZ, retrovirus vector DFG-interleukin (IL)-12, and SFV-IL12, respectively. The results indicated that therapeutic immunization with SFV-IL12 prolonged the survival of mice with established tumors. Semliki Forest virus induces apoptotic death to glioma cells, which facilitates the uptake of apoptotic cells by dendritic cells, providing a potential mechanism for enhanced immunogenicity.
Immunogene therapy with IL-12 via SFV may be an excellent candidate for the development of new cancer vaccines. |
| doi_str_mv | 10.3171/foc.2000.9.6.8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70609070</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70609070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3128-80804b844216d29760e385e3251640a7915a8681895a9d74071e90d1c920b203</originalsourceid><addsrcrecordid>eNpNkU1P3DAQhq2qFVDKtUfkU29Jx07ijyNCpUVC4lDuljeZ3RoSe_EH0v4Zfmudsmp7Gkvz-NE7egn5zKDtmGRft2FsOQC0uhWtekfOGGjegFD9-__ep-RjSo8AHR_kcEJOmVBMCg1n5PXWT2XMLngattTS_Auj3WPJbqTWZ5fLEiJ1y1J8mMPOjXamEdM--IR0c6DO52j_QHXh_CP-de3QY175-UDR75xHjDjRn7jM7snRm1A1mb64WBLNge5jqEFwFWKcsTw53zD-iXzY2jnhxXGek4ebbw_XP5q7---311d3zdgxrhoFCvqN6nvOxMS1FICdGrCey0QPVmo2WFVvVnqwepI9SIYaJjZqDhsO3Tn58qatKZ5LzWUWl0acZ-sxlGQkCNAgV7B9A8cYUoq4NfvoFhsPhoFZCzG1ELMWYrQRRtUPl0dz2Sw4_cOPDXS_AWWziWo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70609070</pqid></control><display><type>article</type><title>Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Yamanaka, R ; Zullo, S A ; Tanaka, R ; Ramsey, J ; Blaese, M ; Xanthopoulos, K G</creator><creatorcontrib>Yamanaka, R ; Zullo, S A ; Tanaka, R ; Ramsey, J ; Blaese, M ; Xanthopoulos, K G</creatorcontrib><description>The authors investigated immunogene therapy for malignant glioma to determine whether its therapeutic efficacy could be improved.
Four groups of 203-glioma-bearing mice were treated with injections of phosphate-buffered saline, Semliki Forest virus (SFV)-LacZ, retrovirus vector DFG-interleukin (IL)-12, and SFV-IL12, respectively. The results indicated that therapeutic immunization with SFV-IL12 prolonged the survival of mice with established tumors. Semliki Forest virus induces apoptotic death to glioma cells, which facilitates the uptake of apoptotic cells by dendritic cells, providing a potential mechanism for enhanced immunogenicity.
Immunogene therapy with IL-12 via SFV may be an excellent candidate for the development of new cancer vaccines.</description><identifier>ISSN: 1092-0684</identifier><identifier>EISSN: 1092-0684</identifier><identifier>DOI: 10.3171/foc.2000.9.6.8</identifier><identifier>PMID: 16817690</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Apoptosis - immunology ; Brain Neoplasms - immunology ; Brain Neoplasms - pathology ; Brain Neoplasms - therapy ; CD8-Positive T-Lymphocytes - immunology ; Cell Line, Tumor ; Cricetinae ; Dendritic Cells - immunology ; Genetic Engineering - methods ; Genetic Therapy - methods ; Glioma - immunology ; Glioma - pathology ; Glioma - therapy ; Immunotherapy - methods ; Interleukin-12 - genetics ; Kidney - cytology ; Mice ; Mice, Inbred C57BL ; Recombinant Proteins - genetics ; Semliki forest virus - genetics ; Survival Rate ; Transfection</subject><ispartof>Neurosurgical focus, 2000-12, Vol.9 (6), p.e7-6</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3128-80804b844216d29760e385e3251640a7915a8681895a9d74071e90d1c920b203</citedby><cites>FETCH-LOGICAL-c3128-80804b844216d29760e385e3251640a7915a8681895a9d74071e90d1c920b203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16817690$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamanaka, R</creatorcontrib><creatorcontrib>Zullo, S A</creatorcontrib><creatorcontrib>Tanaka, R</creatorcontrib><creatorcontrib>Ramsey, J</creatorcontrib><creatorcontrib>Blaese, M</creatorcontrib><creatorcontrib>Xanthopoulos, K G</creatorcontrib><title>Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12</title><title>Neurosurgical focus</title><addtitle>Neurosurg Focus</addtitle><description>The authors investigated immunogene therapy for malignant glioma to determine whether its therapeutic efficacy could be improved.
Four groups of 203-glioma-bearing mice were treated with injections of phosphate-buffered saline, Semliki Forest virus (SFV)-LacZ, retrovirus vector DFG-interleukin (IL)-12, and SFV-IL12, respectively. The results indicated that therapeutic immunization with SFV-IL12 prolonged the survival of mice with established tumors. Semliki Forest virus induces apoptotic death to glioma cells, which facilitates the uptake of apoptotic cells by dendritic cells, providing a potential mechanism for enhanced immunogenicity.
Immunogene therapy with IL-12 via SFV may be an excellent candidate for the development of new cancer vaccines.</description><subject>Animals</subject><subject>Apoptosis - immunology</subject><subject>Brain Neoplasms - immunology</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - therapy</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Cell Line, Tumor</subject><subject>Cricetinae</subject><subject>Dendritic Cells - immunology</subject><subject>Genetic Engineering - methods</subject><subject>Genetic Therapy - methods</subject><subject>Glioma - immunology</subject><subject>Glioma - pathology</subject><subject>Glioma - therapy</subject><subject>Immunotherapy - methods</subject><subject>Interleukin-12 - genetics</subject><subject>Kidney - cytology</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Recombinant Proteins - genetics</subject><subject>Semliki forest virus - genetics</subject><subject>Survival Rate</subject><subject>Transfection</subject><issn>1092-0684</issn><issn>1092-0684</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkU1P3DAQhq2qFVDKtUfkU29Jx07ijyNCpUVC4lDuljeZ3RoSe_EH0v4Zfmudsmp7Gkvz-NE7egn5zKDtmGRft2FsOQC0uhWtekfOGGjegFD9-__ep-RjSo8AHR_kcEJOmVBMCg1n5PXWT2XMLngattTS_Auj3WPJbqTWZ5fLEiJ1y1J8mMPOjXamEdM--IR0c6DO52j_QHXh_CP-de3QY175-UDR75xHjDjRn7jM7snRm1A1mb64WBLNge5jqEFwFWKcsTw53zD-iXzY2jnhxXGek4ebbw_XP5q7---311d3zdgxrhoFCvqN6nvOxMS1FICdGrCey0QPVmo2WFVvVnqwepI9SIYaJjZqDhsO3Tn58qatKZ5LzWUWl0acZ-sxlGQkCNAgV7B9A8cYUoq4NfvoFhsPhoFZCzG1ELMWYrQRRtUPl0dz2Sw4_cOPDXS_AWWziWo</recordid><startdate>20001215</startdate><enddate>20001215</enddate><creator>Yamanaka, R</creator><creator>Zullo, S A</creator><creator>Tanaka, R</creator><creator>Ramsey, J</creator><creator>Blaese, M</creator><creator>Xanthopoulos, K G</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20001215</creationdate><title>Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12</title><author>Yamanaka, R ; Zullo, S A ; Tanaka, R ; Ramsey, J ; Blaese, M ; Xanthopoulos, K G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3128-80804b844216d29760e385e3251640a7915a8681895a9d74071e90d1c920b203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animals</topic><topic>Apoptosis - immunology</topic><topic>Brain Neoplasms - immunology</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - therapy</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Cell Line, Tumor</topic><topic>Cricetinae</topic><topic>Dendritic Cells - immunology</topic><topic>Genetic Engineering - methods</topic><topic>Genetic Therapy - methods</topic><topic>Glioma - immunology</topic><topic>Glioma - pathology</topic><topic>Glioma - therapy</topic><topic>Immunotherapy - methods</topic><topic>Interleukin-12 - genetics</topic><topic>Kidney - cytology</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Recombinant Proteins - genetics</topic><topic>Semliki forest virus - genetics</topic><topic>Survival Rate</topic><topic>Transfection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamanaka, R</creatorcontrib><creatorcontrib>Zullo, S A</creatorcontrib><creatorcontrib>Tanaka, R</creatorcontrib><creatorcontrib>Ramsey, J</creatorcontrib><creatorcontrib>Blaese, M</creatorcontrib><creatorcontrib>Xanthopoulos, K G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurosurgical focus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamanaka, R</au><au>Zullo, S A</au><au>Tanaka, R</au><au>Ramsey, J</au><au>Blaese, M</au><au>Xanthopoulos, K G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12</atitle><jtitle>Neurosurgical focus</jtitle><addtitle>Neurosurg Focus</addtitle><date>2000-12-15</date><risdate>2000</risdate><volume>9</volume><issue>6</issue><spage>e7</spage><epage>6</epage><pages>e7-6</pages><issn>1092-0684</issn><eissn>1092-0684</eissn><abstract>The authors investigated immunogene therapy for malignant glioma to determine whether its therapeutic efficacy could be improved.
Four groups of 203-glioma-bearing mice were treated with injections of phosphate-buffered saline, Semliki Forest virus (SFV)-LacZ, retrovirus vector DFG-interleukin (IL)-12, and SFV-IL12, respectively. The results indicated that therapeutic immunization with SFV-IL12 prolonged the survival of mice with established tumors. Semliki Forest virus induces apoptotic death to glioma cells, which facilitates the uptake of apoptotic cells by dendritic cells, providing a potential mechanism for enhanced immunogenicity.
Immunogene therapy with IL-12 via SFV may be an excellent candidate for the development of new cancer vaccines.</abstract><cop>United States</cop><pmid>16817690</pmid><doi>10.3171/foc.2000.9.6.8</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1092-0684 |
| ispartof | Neurosurgical focus, 2000-12, Vol.9 (6), p.e7-6 |
| issn | 1092-0684 1092-0684 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70609070 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Animals Apoptosis - immunology Brain Neoplasms - immunology Brain Neoplasms - pathology Brain Neoplasms - therapy CD8-Positive T-Lymphocytes - immunology Cell Line, Tumor Cricetinae Dendritic Cells - immunology Genetic Engineering - methods Genetic Therapy - methods Glioma - immunology Glioma - pathology Glioma - therapy Immunotherapy - methods Interleukin-12 - genetics Kidney - cytology Mice Mice, Inbred C57BL Recombinant Proteins - genetics Semliki forest virus - genetics Survival Rate Transfection |
| title | Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T23%3A18%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Induction%20of%20a%20therapeutic%20antitumor%20immunological%20response%20by%20intratumoral%20injection%20of%20genetically%20engineered%20Semliki%20Forest%20virus%20to%20produce%20interleukin-12&rft.jtitle=Neurosurgical%20focus&rft.au=Yamanaka,%20R&rft.date=2000-12-15&rft.volume=9&rft.issue=6&rft.spage=e7&rft.epage=6&rft.pages=e7-6&rft.issn=1092-0684&rft.eissn=1092-0684&rft_id=info:doi/10.3171/foc.2000.9.6.8&rft_dat=%3Cproquest_cross%3E70609070%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70609070&rft_id=info:pmid/16817690&rfr_iscdi=true |